New study provides rationale for use of a multi-target anticancer drug in patients with malignant pleural mesothelioma

The multi-target small molecule anticancer drug nintedanib shows promising effectiveness in stopping the growth of human malignant pleural mesothelioma, a fatal thoracic tumor, in preclinical models, according to a new study published jointly by researchers in Austria, Germany and Hungary. Malignant pleural mesothelioma is a particularly aggressive tumor that occurs in the lining that covers the lungs. It typically results […]
Continue reading »